CLINICAL
TRIAL

Diabetes (Type-2)

Human clinical trials (Phase-||, Phase-|||) Double blind,
Randomized, with Placebo

Clinical Outcome
  • 93% β -cell regeneration
  • β cell proliferation
  • Inhibition of β apoptosis,
  • Reduction in OHA, Insulin (70-100%)
  • Improvement in FBS, PPBS, Homa- β (More than 50%)
  • Reduction in HOMA-IR significantly
  • Improvement in C-Peptide
  • 3.1 HbA1c dropping point
  • 73% Interleukin-1β reduced
  • 28% Interferon-γ decreased
  • 52% Interleukin-6 significantly reduced
  • Insulin production increased by 3 times
  • No evidence of hypoglycemia
  • No fluctuation in Lipid profile, Liver function, Kidney function
  • 10,000+ Satisfied patients till day
  • No Mortality
  • Clinical trial & Case study published
Diabetes (Type-1)

Human clinical trials (Phase-II, Case study)

Clinical Outcome
  • 93% β -cell regeneration
  • β cell proliferation
  • Inhibition of β apoptosis,
  • Reduction in OHA, Insulin
  • Significant Improvement in FBS, PPBS, Homa- β
  • Reduction in HOMA-IR
  • Significant Improvement in C-Peptide, HbA
  • 73% Interleukin-1β reduced
  • 28% Interferon-γ decreased
  • 52% Interleukin-6 significantly reduced
  • Insulin production increased by 3 times
  • No evidence of hypoglycemia
  • No fluctuation in Lipid profile, Liver function, Kidney function
  • Juvenile patient also included
  • 500+ Satisfied patients till day
  • No Mortality
  • Clinical trial and Case study published
Diabetes (Time in Range)

Under process- Human clinical trials & Case study cleared

Clinical Outcome
  • Time in range (97.22%)
  • 97.22% Time in range
  • 2.77 % Time above range
  • 0% Time below range
  • No evidence of Hypoglycaemia
  • No evidence of Diabetic retinopathy, Neuropathy, Microalbuminia
  • No evidence of fluctuation in liver function, kidney function & Lipid profile
  • Case study Published
  • No Mortality
Diabetes (β -cell regeneration)
Clinical Outcome
  • 93% β -cell regeneration
  • β cell proliferation
  • Inhibition of β apoptosis,
  • 73% Interleukin-1β reduced
  • 28% Interferon-γ decreased
  • 52% Interleukin-6 significantly reduced
  • Insulin production increased by 3 times
  • No Mortality
  • Study published
Rheumatoid Arthritis (Ortho)

Human clinical trials (Phase-||, Phase-|||) Double blind,
Randomized, with PlaceboHuman clinical trials (Phase-II, Phase-III) Double blind, Randomized, with Placebo cleared

Clinical Outcome
  • Joint Swelling is found to be reduced from day 7th only
  • Significant reduction in WOMAC (More than 75%)
  • Significant reduction in VAS Score (More than 60%)
  • Significant reduction in CRP (69%), Pain (100%) and related symptoms
  • Significantly improvement in Stiffness, Tiredness, muscles spasm, tenderness &
  • 88% relieved morning stiffness
  • Reduction in inflammatory parameters suggests anti-inflammatory & anti-arthritic action
  • TNF-a levels decreased by 55% (inhibited Necrosis)
  • Leukotriene B4 levels decreased by 57% (Which promotes Arthritis development)
  • Cartilage degenerative MMP-13 levels decreased by 88%
  • COMP levels decreased by 37%
  • IL-6 levels decreased by 61%
  • 10,000 Satisfied patients till day
  • Clinical trial and Case study published
Osteoarthritis (Joint & Muscular)

Human clinical trials (Phase-II, Phase-III) Double blind, Randomized, with Placebo cleared

Clinical Outcome
  • Cartilage regeneration with Chondroprotection proven
  • Synovial fluid regeneration with Chondroregeneration
  • TNF-a levels decreased by 55% (inhibited Necrosis)
  • Leukotriene B4 levels decreased by 57% (Which promotes Arthritis development)
  • CRP levels decreased by 69%
  • Cartilage degenerative MMP-13 levels decreased by 88%
  • COMP levels decreased by 37%
  • IL-6 levels decreased by 61% Joint Swelling is found to be reduced from day 7th only
  • Significant reduction in WOMAC (More than 75%)
  • Significant reduction in VAS Score (More than 60%)
  • Significant reduction in Pain in all subjects.
  • Significantly improvement in Stiffness, Tiredness, muscles spasm, tenderness &
  • 88% relieved morning stiffness
  • Reduction in inflammatory parameters suggests the anti-inflammatory and anti-arthritic action
  • 10,000 Satisfied patients till day.
  • Clinical trial and Case study published
Cartilage regeneration (Chondroregeneration)

Joint Swelling is found to be reduced from day 7th only.

Clinical Outcome
  • Reduction in inflammatory parameters suggests the anti-inflammatory and anti-arthritic action of Gplife Joint Support Product
  • TNF-a levels decreased by 55% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • Leukotriene B4 levels decreased by 57% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • CRP levels decreased by 69% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • MMP-13 levels decreased by 88% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • COMP levels decreased by 37% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • IL-6 levels decreased by 61% in the Gplife Joint Support Product group when compared with the Disease Control group.
  • COMP might therefore be involved in the regeneration efforts of cartilage tissue as a factor secreted by chondrocytes to ameliorate the matrix breakdown. Gplife Joint Support Product can improve the chondrocyte production for the repair of damaged cartilage
  • In this study, we have found that a decrease in MMP-13 stabilizes their extracellular matrix, impaired chondrocyte terminal maturation and enhanced their viability, and inhibited multiple effectors and regulators of chondrocyte differentiation. The decreased levels of MMP-13 indicate the chondroprotective effect and anti-arthritic potential.
  • Research study published
Covid-19 (Coroprotect Kit)

Human clinical trials (Phase-III) Double blind, Randomized, with Placebo & Case study

Clinical Outcome
  • Anti-Sars-Cov-2 proven (95 % Sars-Cov-2 inhibition in 24 hours) as per DBT lab.
  • 4-7 days RTPCR Negativity
  • Significantly reduction in CRP, LDH, IL-6, Ferritin, D-Dimmer found with improvement in Platelets, WBC, HB.
  • Docking study with 6M71 Sars-Protein proven inhibit viral load.
  • CD-3, CD-4, CD-8, CD-45 Significantly improve indicated immunomodulatory effects.
  • Anti-Oxidant, Antiviral study proven.
  • 10,000+ patients recovered till day.
  • No Mortality
  • Clinical trial and Case study published
ACT-12, ACT-13 (Antiviral & Immunomodulator)

Human clinical trials (Phase-II) Double blind, Randomized, with Placebo & Case study

Clinical Outcome
  • Anti-Sars-Cov-2 proven (96 % Sars-Cov-2 inhibition in 24 hours) as per DBT lab.
  • 4-7 days RTPCR Negativity
  • Post covid Pneumonia recovered in 10 days
  • Significantly reduction in CRP, LDH, IL-6
  • Ferritin, D-Dimmer found with improvement in WBC, HB
  • Thrombocytopenia improvement found (Anti-Dengue activity)
  • Docking study with 6M71 Sars-Protein proven inhibit viral load of covid-19
  • CD-3, CD-4, CD-8, CD-45 Significantly improve indicated immunomodulatory effects
  • Anti-Oxidant, Antiviral study proven
  • Regeneration of Post covid lung damage as per case study
  • 10,000+ Satisfied patients till day.
  • No Mortality
  • Clinical trial and Case study published
Respiratory illness (Cough & Cold)

Human clinical trials (Phase-II) Double blind, Randomized, with Placebo & Case study

Clinical Outcome
  • 83.3% subjects were relieved of cough with daytime cough
  • 90% subjects were relieved of cough with night cough
  • More than 90% subjects were relieved of throat irritation and chest pain
  • More than 90% subjects were relieved of wheezing and shortness of breath
  • 100% subjects were relieved of throat clearing & Sore throat
  • There is no recurrence after stoppage of medicine & Proven safe for long term use
  • It is proven best as an Anti-infective for respiratory illness
  • More than 95% subject were relieved of time to relief from cough and throat irritation for all first morning dose
  • No evidence of fluctuation in liver function test, kidney function test and lipid profile
  • Significantly reduction in CRP, ESR
  • 100000+ Satisfied patients till day
  • No Mortality
  • Clinical trial published and Case study under publication
Digestive (Gastrointestinal Disease)

Human clinical trials (Phase-II) Double blind, Randomized, with Placebo & Case study

Clinical Outcome
  • Significant Improvements in epigastric discomfort and heartburn due to hyper acidity
  • 100% Subjects relived from nausea, vomiting
  • 100% Subject starts to relieves constipation in 2-3 days without diarrhoea
  • More than 85% subject relieves from Constipation and Hyperacidity
  • More than 90% subject relieves from Bloating and post prandial fullness
  • More than 50% subjects got relief from indigestion, Belching flatulence, fullness in stomach, abdominal distension
  • From observation, it was found improvement in intestinal motility
  • This formulation on gastrointestinal health observed Less events of abdominal discomfort, hence proven safe for long term use
  • No evidence of fluctuation in liver function test, kidney function test and lipid profile
  • Improvements in overall health and quality of life
  • No Mortality
  • Paper Under publication
Piles & Haemorrhoids (Gut)

In process- Human clinical trials (Phase-II) & Case study cleared

Clinical Outcome
  • Haemorrhoids (Piles bleeding) stopped in 3 days after treatment.
  • Piles inflammation starts to reduced by 50-80% in 3-5 days
  • Piles pain start to reduced by next day of treatment and complete relieves in 5-7 days.
  • Significant improvement found in fissure and fistula also.
  • Subject relieves constipation during treatment and stool appearance also smooth lead decrease piles pain.
  • During clinical study it was found beneficial in both internal and external piles.
Hyperlipidaemia (Cardiovascular)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • Significantly improvement found in Total lipid profile
  • 60-80% reduction found in LDL in all subjects (90days)
  • Significant improvement found in HDL (90 days)
  • More than 50% reduction found in Triglycerides
  • VLDL ratio also improve in 90 days
  • Improvement found in Stress, chest pain and Shortness of breathing
  • Improvement found in quality of life
  • 5-8% Weight reduction found in obese patient
  • 10,000+ patients satisfied till date
  • No Mortality
  • Clinical trial running on and Case study under publication
Kidney stone (CKD)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • Significantly reduction in Painful urination
  • Stone fragmentation and dissolution found during line of treatment
  • Reduction in Prostate inflammation found in male
  • It was observed that diuretic effect starts from 1-2 days
  • Improvement found in Bilirubin, Albumin, Globulin, S- Creatinine, and GAMMA GT in 60 days.
  • 1000+ patients recovered till day.
  • No Mortality
  • Clinical trial is under process and Case study is about to publish
NAFLD (Fatty liver)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • In radiological finding significant reduction found in fat and inflammation of liver in 60 days.
  • Significantly reduction in SGOT, SGPT, GAMMA GT, Total bilirubin found in 60 days.
  • As per observation, it relieves Stomach (Liver) pain, Poor metabolism, Jaundice and poor appetite.
  • In all subject, digestion & quality of life found better during treatment
  • 500+ patients satisfied till date (Some subjects are AFLD)
  • No Mortality
  • Clinical trial and Case study published
Oligospermia (Men fertility)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • 40-50% improvement found in Sperm motility & Sperm count in 60 days
  • Symptomatic improvement found in Libido, Vitality, Endurance
  • 1000+ patients recovered till day
  • Clinical trial and Case study published
B12 Deficiency (Tingling, Numbness)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • 70-80 % improvement found in B12 in 60 days
  • Symptomatic improvement found in Focus, Alert, Tingling, Numbness & Endurance
  • Significantly reduction found in body ache due to B12 deficiency
  • 1000+ patients satisfied till date
  • Publication is under process
Weight loss (Obesity)

In process-Human clinical trials & Case study cleared

Clinical Outcome
  • Monthly 1-4 kg weight reduction found
  • Patient with constipation also resolved during treatment
  • None of patients suffering from diarrhoea, gastric trouble or weakness during treatment
  • After 90 days of treatment, inches loss found in some of high obese patient
  • Some patient on Diet, Yoga and Exercise adjunctly also seems good response.
  • 1000+ patients satisfied till date
  • Publication is under process